Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Recruiting
Observational Study
Disease/Condition Name Cancer-related Cognitive Dysfunction
Chronic Lymphocytic Leukemia (CLL)
Chronic Myeloid Leukemia, BCR-ABL1 Positive
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 400 (estimated)
- Sponsor
- University of Rochester NCORP Research Base · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* TKI RECIPIENTS: Participants must have a diagnosis of CML or CLL
* TKI RECIPIENTS: Participants must be scheduled to receive their first dose of TKI therapy for CML or CLL within 30 days or have received their first dose of TKI therapy for CML or CLL within the previous 30 day…
Contacts